Abstract
A prospective, non-randomized, multicentre, open, dose-finding study of a carboplatin-docetaxel (C-D) combination as first-line chemotherapy in FIGO stage Ic–IV epithelial ovarian cancer. C-D was given 3-weekly for 6 planned cycles, with a 3-day prophylactic dexamethasone regimen (8 mg b.i.d.). 139 eligible patients (Pts) (median age 56 years, range 28–85) were given a total of 750 cycles of chemotherapy in 5 cohorts: Co1, 32 pts, 169 cycles (C at AUC 5 + D 60 mg/m2); Co2, 22 pts, 122 cycles (5 + 75), Co3, 29 pts, 156 cycles (6 + 75), Co4, 27 pts, 146 cycles (7 + 75), Co5, 30 pts, 157 cycles (6 + 85). 110 patients (79%) completed 6 cycles; 17 (12%) stopped due to toxicity. 104 patients (75%) had CTC grade IV neutropenia, and 5 patients (4%) had this associated with fever. There were 2 probable treatment-related deaths. Only 8 patients (6%) experienced grade II–III neurotoxicity (all sensory; no motor > grade I). The maximum tolerated dose was reached in cohorts 4 and 5, and the dose limiting toxicities were myelosuppression and diarrhoea. The overall response rate for the study was 66% (49/74); CA125 response was 75% (70/93). Median progression-free survival was 16.6 months (95% CI 13.3–19.1). Recommended doses are carboplatin AUC 5 (via51Cr EDTA) or AUC 6 (if calculated) plus docetaxel 75 mg/m2. A randomized trial comparing this regimen with carboplatin-paclitaxel has just completed recruitment. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Aabo K, Adams M, Adnitt P, Alberts DS, Athanazziou A, Barley V, Bell DR, Bianchi U, Bolis G, Brady MF, Brodovsky HS, Bruckner H, Buyse M, Canetta R, Chylak V, Cohen CJ, Colombo N, Conte PF, Crowther D, Edmonson JH, Gennatas C, Gilbey E, Gore M, Guthrie D and Yeap BY (1998) Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomised trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer 78: 1479–1487
A'hern RP and Gore ME (1995) Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 13: 726–732
Bolis G, Scarfone G, Villa A, Acerboni S, Siliprandi V and Guarnerio P (1997) A phase I–II trial of fixed-dose carboplatin and escalating paclitaxel in advanced ovarian cancer. Eur J Cancer 33: 592–595
Bookman MA, McGuire WP 3rd, Kilpatrick D, Keenan E, Hogan WM, Johnson SW, O'Dwyer P, Rowinsky E, Gallion HH and Ozols RF (1996) Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynaecologic Oncology Group. J Clin Oncol 14: 1895–1902
Brown R, Hirst GL, Gallagher WM, McIlwrath AJ, Margison GP, van der Zee AG and Anthoney DA (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15: 45–52
Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D and Kaye SB (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatinum. Cancer Chemother Pharmacol 41: 161–166
Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME and Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748–1756
Calvert AH, Boddy A, Bailey NP, Siddiqui N, Humphreys A, Hughes A, Robson L, Gumbrell L and Thomas H (1995) Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. Semin Oncol 22: 91–98 (suppl 12)
Chan S, Friedrichs K, Noel D, Duarte R, Vorobiof D, Pinter T, Yelle L, Alaki M, Murawsky M and Riva A (1997) A randomised phase III study of taxotere (T) versus doxorubicin (D) in patients with metastatic breast cancer who have failed an alkylating containing regimen: preliminary results. Proc Am Soc Clin Oncol 16: 540 (abstr)
Chantler C, Garnett ES, Parsons V and Veall N (1969) Glomerular filtration rate measurement in man by the single injection method using51CrEDTA. J Clin Sci 37: 169–190
Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C and Anker P (1996) Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nature Med 2: 1033–1035
Docetaxel Investigator's Brochure, Rhone-Poulenc Rorer Recherche-Developpement, Antony cedex, France. Version 8; 1 September, 1999
duBois A, Luck HJ and Baucknecht T (1997) Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol 8: 355–361
duBois A, Lueck HJ, Meier W, Moebus V, Costa SD, Bauknecht T, Richter B, Warm M, Schroeder W, Olbricht S, Nitz U and Jackisch C (1999) Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) study group trial. Proc Am Soc Clin Oncol 18: 1374 (abstr)
Eatock M, Paul J and Kaye SB (1999) A new tool for assessing chemotherapy-induced neuropathy. Br J Cancer 80: 111 (suppl 2)
Gianni L (1995) Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol 6: 861–863
Hilkens PH, Verweij J, Stoter G, Vecht CJ, van Putten WL and van den Bent MJ (1996) Peripheral neurotoxicity induced by docetaxel. Neurology 46: 104–108
Hilkens PH, Pronk LC, Verweij J, Vecht CJ, van Putten WL and van den Bent MJ (1997) Peripheral neuropathy induced by combination chemotherapy of docetaxel and cisplatin. Br J Cancer 75: 417–422
Hill M, Macfarlane V, Moore J and Gore ME (1997) Taxane/Platinum/Anthracycline combination therapy in advanced epithelial ovarian cancer. Semin Oncol 24: 34–37 (suppl 2)
Huizing MT, van Warmerdam LJ, Rosing H, Schaefers MC, Lai A, Helmerhorst TJ, Veenhof CH, Birkhofer MJ, Rodenhuis S, Beijnen JH and ten Bokkel Huinink WW (1997) Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer. J Clin Oncol 15: 1953–1964
Kaye SB, Piccart M, Aapro M, Francis P and Kavanagh J (1997) Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer – an updated overview. Eur J Cancer 33: 2167–2170
Kavanagh JJ, Winn R, Steger M, Nelson-Taylor T, Edwards K, Rodgers R, James Borst, Kudelka AP, Hu W and Verschraegen CF (1999) Docetaxel for patients with ovarian cancer refractory to paclitaxel, an update. Proc Am Soc Clin Oncol 18: 1423 (abstr)
Kunitoh H, Saijo N, Furuse K, Noda K and Ogawa M (1998) Neuromuscular toxicities of paclitaxel 210 mg/m2by 3-hour infusion. Br J Cancer 77: 1686–1688
Lhomme C, Kerbrat P, Lejeune C, Guastalla JP, Fumoleau P, Goupil A, Heron JF, Cassin MA, Pruvot I, Soares JA and Chazard M (1996) Carboplatin plus paclitaxel in the first-line treatment of advanced ovarian cancer: preliminary results of a phase I study. Semin Oncol 23: 48–54 (suppl 12)
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1–6
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 74: 207–214
Nawroz H, Koch W, Anker P, Stroun M and Sidransky D (1996) Microsatellite alterations in serum DNA of head and neck cancer patients. Nature Med 2: 1035–1037
Neijt JP, Hansen SW, Hansen SW, Sorensen PG, Sessa C, Witteveen PO, Engelholm SA, Stigaard L, Roer O and Lund B (1997) Randomised phase III study in previously untreated epithelial ovarian cancer FIGO stage IIB, IIC, III, IV, comparing paclitaxel-cisplatin and paclitaxel-carboplatin. Proc Am Soc Clin Oncol 16: 1259 (abstr)
New PZ, Jackson CE, Rinaldi D, Burris H and Barohn RJ (1996) Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology 46: 108–111
Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ and Park RC (1991) Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: The Gynaecologic Oncology Group experience. J Clin Oncol 9: 1138–1150
Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Mannel R, Hartenback EM and Baergen R (1999) Randomised phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): A Gynaecologic Oncology Group Trial (GOG 158). Proc Am Soc Clin Oncol 18: 1373 (abstr)
Paridaens R, Bruning P, Klijn J, Gamucci T, Biganzoli L, Van Vreckem A, Hoctin Boes G and Piccart M (1997) An EORTC crossover trial comparing single agent Taxol (T) and doxorubicin (D) as first-and second-line chemotherapy in advanced breast cancer (ABC). Proc Am Soc Clin Oncol 16: 539 (abstr)
Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Trimmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B and Pecorelli S (2000) Randomised intergroup trial of cisplatin-paclitaxel versus csiplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699–708
Pitei DL, Watkins PJ, Stevens MJ and Edmonds ME (1994) The value of the neurometer in assessing diabetic neuropathy. Diabetic Med 11: 872
Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G and Zunino F (1996) A comparative study of p53 gene mutations, protein accumulation and response to cisplatin-based chemotherapy in advanced ovarian cancer. Cancer Res 56: 689–693
Rowinsky EK, Chaudhry V, Cornblath DR and Donehower RC (1993) Neurotoxicity of Taxol. J Natl Cancer Inst Monographs, 107–115
Rustin GJ, Nelstrop AE, McClean P, Brady MF, McGuire WP, Hoskins WJ, Mitchell H and Lambert HE (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA125. J Clin Oncol 14: 1545–1551
Siddiqui N, Boddy AV, Thomas HD, Bailey NP, Robson L, Lind MJ and Calvert AH (1997) A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer 75: 287–294
Strathdee G, MacKean MJ, Illand M and Brown R (1999) A role for methylation of the hMLH1 promotor in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18: 2335–2341
ten Bokkel Huinink WW, van Warmerdam LJ, Helmerhorst TJ, Schaefers MC, Beijnen JH and Rodenhuis S (1997) Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer. Ann Oncol 8: 351–354
Valero V (1996) Treatment of patients resistant to paclitaxel therapy. Anticancer Drugs 7: 17–19 (suppl 2)
Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, Atkinson R, Graham J, Crawford SM, Coleman R, Thomas H, Davis J, Eggleton SP and Kaye SB (1999a) Docetaxel-cisplatin in combination as first-line chemotherapy for advanced epithelial ovarian cancer. J Clin Oncol 17(7): 2069–2080
Vasey PA, Reed NS, Davis J, Paul J, Fleming D, Yosef H, Eggleton P and Kaye SB (1999b) Dose-finding study of carboplatin-epirubicin-docetaxel in advanced epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 18: 1490 (abstr)
Yancik R (1993) Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 71: 517–523, (suppl 2)
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Vasey, P., Atkinson, R., Coleman, R. et al. Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 84, 170–178 (2001). https://doi.org/10.1054/bjoc.2000.1572
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1572
Keywords
This article is cited by
-
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study
International Journal of Clinical Oncology (2013)
-
Therapeutic strategies in epithelial ovarian cancer
Journal of Experimental & Clinical Cancer Research (2012)
-
Purine Nucleoside Phosphorylase mediated molecular chemotherapy and conventional chemotherapy: A tangible union against chemoresistant cancer
BMC Cancer (2011)
-
Combination of docetaxel-carboplatin for adjuvant chemotherapy of epithelial ovarian, primary peritoneal and fallopian tube cancers: a meta-analysis
The Chinese-German Journal of Clinical Oncology (2010)
-
A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer
International Journal of Clinical Oncology (2007)
